Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development
1st Bio Therapeutics Inc
Alterity Therapeutics Ltd
Arvis Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Corestem Inc
Deli Therapeutics Inc
EmeraMed Ltd
ICB Intertiol Inc
Inhibikase Therapeutics Inc
Ionis Pharmaceuticals Inc
MitoDys Therapeutics Ltd
Modag GmbH
Neuropore Therapies Inc
Newron Pharmaceuticals SpA
ProMIS Neurosciences Inc
Stealth BioTherapeutics Corp
United Neuroscience Ltd
Voyager Therapeutics Inc
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drug Profiles
1ST-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AHT-434 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anle-138b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha Synuclein for Parkinson’s Disease and Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-10BR05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emeramide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapies to Inhibit SNCA for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IkT-148X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ION-464 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit Alpha Synuclein for Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-20011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
safimide mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-272 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurodegenerative Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verdiperstat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Dormant Projects
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Product Development Milestones
Featured News & Press Releases
May 20, 2020: Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Mar 18, 2020: Biohaven’s Verdiperstat receives fast track desigtion for the treatment of multiple system atrophy
Jan 14, 2020: European Commission approves Orphan Desigtion for Alterity’s lead drug candidate
Dec 18, 2019: MODAG initiates first-in-human phase 1 clinical trial for Anle138b
Nov 18, 2019: Alterity’s lead drug candidate receives positive opinion from European medical agency
Oct 17, 2019: Arvis to Present update on Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson’s Disease at the 2nd Targeted Protein Degradation Summit
Sep 25, 2019: Alterity presents clinical data on PBT434 at the 2019 MDS Congress
Aug 01, 2019: Biohaven initiates enrolment in verdiperstat’s study for MSA
Jul 29, 2019: Alterity Therapeutics announces successful completion of phase 1 clinical trial
May 07, 2019: Biohaven provides update on verdiperstat from its MPO platform
May 06, 2019: Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting
May 03, 2019: Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting
Apr 10, 2019: Alterity Therapeutics launches to Asian investors
Feb 19, 2019: Biohaven’s Verdiperstat receives Orphan Drug Desigtion From FDA For multiple system atrophy
Jan 31, 2019: Pra receives Orphan Desigtion for PBT434 for treatment of MSA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by 1st Bio Therapeutics Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Alterity Therapeutics Ltd, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Arvinas Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Biogen Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Corestem Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Denali Therapeutics Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by EmeraMed Ltd, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by ICB International Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Inhibikase Therapeutics Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Ionis Pharmaceuticals Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by MitoDys Therapeutics Ltd, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Modag GmbH, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Neuropore Therapies Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Newron Pharmaceuticals SpA, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by ProMIS Neurosciences Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Stealth BioTherapeutics Corp, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by United Neuroscience Ltd, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Voyager Therapeutics Inc, H1 2020
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Dormant Projects, H1 2020